Bristol Myers Squibb will become responsible for the development and any marketing of DF6002 and its related products worldwide ... it plans to advance R&D in oncology and haematology and is ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Overall, BMS reported a 2% rise in second-quarter revenues to $11.9 billion, led once again by Opdivo and anti-thrombotic drug Eliquis (apixaban) but backed by a series of new products that ...

The CHMP recommends approval of Bristol Myers' Opdivo plus Yervoy for the first-line treatment of hepatocellular carcinoma ...

Bristol Myers Squibb’s Opdivo plus Yervoy, as well as Pfizer’s Braftovi, have each shown strong Phase III performances that ...

The committee reviewed data showing a 94 percent complete response rate as a third- or later-line treatment for refractory follicular lymphoma.